Member Info for Timster

Big Als ready

https://youtu.be/Pgmvuj86VcA?t=1782

It's all turned out rather well since he turned up MASSIVE LOLZ

So let's be down to earth and realistic mologic went from 92/100 to this.

So in theory we could drop too.

But why did mologic form a commercial partnership with us 8 days before this data was obtained after and I quote "am very pleased to announce this partnership with Mologic, which follows a close collaboration over recent months"

More proof if needed that it's not the government test

Interesting, 8 days after they announced the commercial partnership with Avacta

It's not the shorters is the ODX clowns on tour

Well we'll find out in the next couple of weeks I promise not to troll your board if it's us

Could you give us a run down of why we should move to ODX? Here's 34 reasons why we like our Avacta investment. At least 5 of those could be worth billions on thier own merit.

Could you point us to ODX sales figures and money in the bank?

Affimer tech can propel Avacta into Blockbuster sales.
Major Pharms & Diagnostics firms have licences and products with Avacta
Daewoong,Moderna,LG Chem,Bruker,ADC,Point,
Astrea,Mologic,Deepverge,Tufts, the more companies that licence affimers the harder and more costly it will be to buy out Avacta.

Oncology x 11
Ava6000,AVA7500,
AVA028,AVA7000,AVA004
AVA027,AVA3996 plus 4 undisclosed targets
Covid x 5
Affidx, Bams,Elisa,
Saliva,Spitaffidx (You can have that one Big Al)
Mologic combination test.
Plus in house pipe line non-COVID diagnostic tests, which include assays for D-dimer, cortisol, vitamins D and B12 and CRP.
LG Chem x 8
Every RNS states a multi-target deal with LG Chem worth up to $400m.
In the business update $98 million for the 2 below and up to $55m for each new product
So LG Chem has potentially 8 new products.
multi-target collaboration with LG Chem incorporating Avacta's Affimer XT™ serum half-life extension and LG Chem has Affimer PD-L1 inhibitortotalling $98million
The expanded partnership also provides LG Chem with rights to develop and commercialise other Affimer and non-Affimer biotherapeutics combined with Affimer XT half-life extension for a range of indications and Avacta could earn an additional $55m in milestone payments for each of these new products.
Daewoong x 2
Gene & stem cell with other targets
Point x 1
radiopharmaceutical prodrug
ADC x 3
three undisclosed cancer targets and provide these to ADC Therapeutics
Moderna x 1
exclusive license agreement with respect to certain Affimer molecules
Astrea x 1
Deepverge x 1
Biokit x 1

@doggy , a joke! WTF a. RNS always follows a 1 code (eventually)

Eh.... What...... are we on the NASDAQ?

That's not BAMS

I'm bumping my own post but listen to how confident big Al is...

There is no question we will deliver a test! But on the cautious side until we know the full CV we wont know how successful that test will be, initial CV gives us a very good idea though.

its with Bruker and Adeptrix so out of Avacta's hands but they are focused on LFT now as number one priority

https://youtu.be/Pgmvuj86VcA?t=3055

I think people will be much more likely to play ball if they know it's a good solid British test.

https://youtu.be/Pgmvuj86VcA?t=1782

no squeaky bum for me.

Alistair said we WILL deliver

It's exactly as the email in the tweet the other day, gov test is not mologic

Great news for us, another good day on an ODX RNS:)

Affimers are k8ng in LFT and sewage monitoring, it's win win avacta...

For balance not all the 34 opportunities could be worth billions, but probably 5 or 6 of them are.
The others are worth millions to 100s of millions

£2.82 Monday
£2.94 Tuesday
£5.12 Wednesday
£10.20 Thursday
£200 Friday